Cagrilintide Peptide

Everyone knows the pancreas makes insulin. It also makes this, in the same granules, at the same time.

Cagrilintide is a long-acting amylin analogue of 37 amino acids built on a pramlintide-derived backbone, with a disulphide bridge between cysteines 2 and 7, a C-terminal amide, and N-terminal acylation at lysine 1 through a gamma-glutamate linker to a C20 fatty diacid. It is investigational and approved nowhere, and Novo Nordisk filed the CagriSema combination of cagrilintide with semaglutide with the FDA on 18 December 2025.

Ask anybody what the pancreas makes and you'll get insulin. Correct, and incomplete.

The beta cells that release insulin release something else at the same time, out of the same granules, in roughly a one-to-hundred ratio.

Cagrilintide is a long-acting analogue of it.

And here's the thing that makes it a chemistry problem rather than a copying exercise. Human amylin aggregates. Left alone in solution it clumps into fibrils, which makes it miserable to formulate and worse to study.

So the analogue exists partly to do the signalling and partly just to stay dissolved long enough to be usable.

A molecule that had to be redesigned before anybody could properly ask what it does.

A hormone that is famously difficult to work with, made cooperative.

Look, most of this shelf is molecules built to hit a receptor harder or longer. This one had a different first problem.

Human amylin is sticky. Not sticky in a useful way, sticky in a falls-out-of-solution-and-forms-fibrils way, which is the same behaviour that makes several unrelated proteins a nuisance in biology.

So the analogue carries substitutions that stop the aggregation, plus the same trick running through this whole catalogue: a lipid modification that grips albumin and stretches the half-life into weekly territory.

Amylin signals through a receptor complex rather than a single clean receptor, which is a genuinely awkward thing to characterise. Calcitonin receptor plus accessory proteins, and the combination determines what binds.

Here's the honest part. Receptor pharmacology here is messier than the GLP-1 story, and anybody presenting it as tidy is smoothing it out for you.

We would rather hand you a complicated answer than a clean wrong one.

Studied mostly as one half of a pair, which makes reading it on its own harder than it looks.

This one comes with a reading problem attached, and it is worth naming before you go looking.

Most of the published work studies cagrilintide alongside a GLP-1 analogue rather than on its own.

There is standalone work. There is considerably more combination work, because that is where the programme went.

So if you are reading the file, check what the arm actually contained before you attribute anything to this molecule specifically. It is the single easiest mistake to make here and the forums make it constantly.

And the ceiling, plainly: approved nowhere. Not in Canada, not anywhere.

Endpoint numbers exist and they belong in the journals that ran them, not on a page selling powder.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Then into the fridge. Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.

It was developed as half of something. Novo Nordisk developed cagrilintide primarily as the amylin component of CagriSema, not as a standalone product. Its own trial shows it underperforming semaglutide alone. That is worth knowing before you buy it on its own.